Skip to content

Study · In vitro (cells) · mouse · 2009

9 results

Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.

Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M, Melmed S

The Journal of clinical endocrinology and metabolism9 Oct 2009Cited by 56 (Europe PMC)

PMID19820006 (opens in a new tab)DOI10.1210/jc.2009-1311 (opens in a new tab)PepBankPUB-19820006
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In mouse corticotroph cells, pasireotide was more potent than octreotide.

    In plain wordsIn cells from mouse pituitary tumors, pasireotide was more potent than octreotide.

    Peptide
    Pasireotide
    Outcome
    IncreaseCorticotroph potency versus octreotide
    Study

    mousen: not reported in source

    Pituitary corticotroph tumor cells
    Comparator
    Octreotide
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We show that pasireotide was more potent than either octreotide or somatostatin-14 in mouse corticotroph cells.
    1 context sentence
    Summary · context
    We used AtT20 mouse pituitary corticotroph tumor cells stably overexpressing SST2 or SST5 and TtT/GF mouse pituitary folliculostellate cells stably or transiently expressing SST receptors to examine ligand-receptor activation by SST2- and SST5-selective agonists.
  2. 02LabIn vitro (cells)Mechanism

    In mouse corticotroph cells, pasireotide was more potent than somatostatin-14.

    In plain wordsIn cells from mouse pituitary tumors, pasireotide was more potent than somatostatin-14.

    Peptide
    Pasireotide
    Outcome
    IncreaseCorticotroph potency versus somatostatin-14
    Study

    mousen: not reported in source

    Pituitary corticotroph tumor cells
    Comparator
    Somatostatin-14
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We show that pasireotide was more potent than either octreotide or somatostatin-14 in mouse corticotroph cells.
    1 context sentence
    Summary · context
    We used AtT20 mouse pituitary corticotroph tumor cells stably overexpressing SST2 or SST5 and TtT/GF mouse pituitary folliculostellate cells stably or transiently expressing SST receptors to examine ligand-receptor activation by SST2- and SST5-selective agonists.
  3. 03LabIn vitro (cells)Mechanism

    In mouse pituitary cells, pasireotide did not induce SST2 internalization.

    In plain wordsIn mouse pituitary cells, pasireotide did not cause SST2 receptors to enter cells.

    Peptide
    Pasireotide
    Outcome
    No significant changeSST2 internalization
    Study

    mousen: not reported in source

    Pituitary corticotroph tumor cells
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pasireotide also does not induce SST2 internalization
    1 context sentence
    Summary · context
    We used AtT20 mouse pituitary corticotroph tumor cells stably overexpressing SST2 or SST5 and TtT/GF mouse pituitary folliculostellate cells stably or transiently expressing SST receptors to examine ligand-receptor activation by SST2- and SST5-selective agonists.
  4. 04LabIn vitro (cells)Mechanism

    In mouse pituitary cells, brief pasireotide exposure prolonged inhibition of forskolin-induced cAMP accumulation, unlike comparator agonists with postwithdrawal rebound.

    In plain wordsIn mouse pituitary cells, pasireotide prolonged suppression of forskolin-induced cAMP, while comparator agonists produced rebound after withdrawal.

    Peptide
    Pasireotide
    Outcome
    DecreaseForskolin-induced cAMP accumulation
    Study

    mousen: not reported in source

    Pituitary corticotroph tumor cells
    Comparator
    Somatostatin-14
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, short exposure to pasireotide causes prolonged inhibition of forskolin or CRH-induced cAMP accumulation, in contrast to somatostatin-14- and SST2-selective agonists that induced postwithdrawal cAMP rebound.
    1 context sentence
    Summary · context
    We used AtT20 mouse pituitary corticotroph tumor cells stably overexpressing SST2 or SST5 and TtT/GF mouse pituitary folliculostellate cells stably or transiently expressing SST receptors to examine ligand-receptor activation by SST2- and SST5-selective agonists.
  5. 05LabIn vitro (cells)Mechanism

    In mouse pituitary cells, brief pasireotide exposure prolonged inhibition of CRH-induced cAMP accumulation, unlike comparator agonists with postwithdrawal rebound.

    In plain wordsIn mouse pituitary cells, pasireotide prolonged suppression of CRH-induced cAMP, while comparator agonists produced rebound after withdrawal.

    Peptide
    Pasireotide
    Outcome
    DecreaseCRH-induced cAMP accumulation
    Study

    mousen: not reported in source

    Pituitary corticotroph tumor cells
    Comparator
    Somatostatin-14
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, short exposure to pasireotide causes prolonged inhibition of forskolin or CRH-induced cAMP accumulation, in contrast to somatostatin-14- and SST2-selective agonists that induced postwithdrawal cAMP rebound.
    1 context sentence
    Summary · context
    We used AtT20 mouse pituitary corticotroph tumor cells stably overexpressing SST2 or SST5 and TtT/GF mouse pituitary folliculostellate cells stably or transiently expressing SST receptors to examine ligand-receptor activation by SST2- and SST5-selective agonists.
  6. 06LabIn vitro (cells)Mechanism

    In mouse pituitary cells, pasireotide prolonged inhibition of forskolin-induced cAMP accumulation, while SST2-selective agonists produced rebound after withdrawal.

    In plain wordsIn mouse pituitary cells, pasireotide prolonged suppression of forskolin-induced cAMP, while SST2-selective agonists produced rebound after withdrawal.

    Peptide
    Pasireotide
    Outcome
    DecreaseForskolin-induced cAMP accumulation versus SST2 agonists
    Study

    mousen: not reported in source

    Pituitary corticotroph tumor cells
    Comparator
    SST2-selective agonists
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, short exposure to pasireotide causes prolonged inhibition of forskolin or CRH-induced cAMP accumulation, in contrast to somatostatin-14- and SST2-selective agonists that induced postwithdrawal cAMP rebound.
    1 context sentence
    Summary · context
    We used AtT20 mouse pituitary corticotroph tumor cells stably overexpressing SST2 or SST5 and TtT/GF mouse pituitary folliculostellate cells stably or transiently expressing SST receptors to examine ligand-receptor activation by SST2- and SST5-selective agonists.
  7. 07LabIn vitro (cells)Mechanism

    In mouse pituitary cells, pasireotide prolonged inhibition of CRH-induced cAMP accumulation, while SST2-selective agonists produced rebound after withdrawal.

    In plain wordsIn mouse pituitary cells, pasireotide prolonged suppression of CRH-induced cAMP, while SST2-selective agonists produced rebound after withdrawal.

    Peptide
    Pasireotide
    Outcome
    DecreaseCRH-induced cAMP accumulation versus SST2 agonists
    Study

    mousen: not reported in source

    Pituitary corticotroph tumor cells
    Comparator
    SST2-selective agonists
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, short exposure to pasireotide causes prolonged inhibition of forskolin or CRH-induced cAMP accumulation, in contrast to somatostatin-14- and SST2-selective agonists that induced postwithdrawal cAMP rebound.
    1 context sentence
    Summary · context
    We used AtT20 mouse pituitary corticotroph tumor cells stably overexpressing SST2 or SST5 and TtT/GF mouse pituitary folliculostellate cells stably or transiently expressing SST receptors to examine ligand-receptor activation by SST2- and SST5-selective agonists.
  8. 08LabIn vitro (cells)Mechanism

    In mouse pituitary cells, pasireotide attenuated octreotide-induced SST2 internalization only at superphysiological doses.

    In plain wordsIn mouse pituitary cells, adding pasireotide reduced SST2 internalization compared with octreotide alone, only at superphysiological doses.

    Peptide
    Pasireotide
    Outcome
    DecreaseOctreotide-induced SST2 internalization
    Study

    mousen: not reported in source

    Pituitary corticotroph tumor cells
    Comparator
    Octreotide alone
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    superphysiological dose rangesAs given in this study (mouse).

    Source sentences

    Summary
    Pasireotide also does not induce SST2 internalization and attenuates octreotide or SRIF14-induced SST2 internalization only at superphysiological dose ranges.
    1 context sentence
    Summary · context
    We used AtT20 mouse pituitary corticotroph tumor cells stably overexpressing SST2 or SST5 and TtT/GF mouse pituitary folliculostellate cells stably or transiently expressing SST receptors to examine ligand-receptor activation by SST2- and SST5-selective agonists.
  9. 09LabIn vitro (cells)Mechanism

    In mouse pituitary cells, pasireotide attenuated SRIF14-induced SST2 internalization only at superphysiological doses.

    In plain wordsIn mouse pituitary cells, adding pasireotide reduced SST2 internalization compared with SRIF14 alone, only at superphysiological doses.

    Peptide
    Pasireotide
    Outcome
    DecreaseSRIF14-induced SST2 internalization
    Study

    mousen: not reported in source

    Pituitary corticotroph tumor cells
    Comparator
    SRIF14 alone
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    superphysiological dose rangesAs given in this study (mouse).

    Source sentences

    Summary
    Pasireotide also does not induce SST2 internalization and attenuates octreotide or SRIF14-induced SST2 internalization only at superphysiological dose ranges.
    1 context sentence
    Summary · context
    We used AtT20 mouse pituitary corticotroph tumor cells stably overexpressing SST2 or SST5 and TtT/GF mouse pituitary folliculostellate cells stably or transiently expressing SST receptors to examine ligand-receptor activation by SST2- and SST5-selective agonists.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.